Impact of adjuvant chemotherapy and patient age on patterns of metastatic recurrence in stage III colorectal cancer.
Grace Gard, Yat Hang To, Lucy Gately, Matthew Croxford, Ian Jones, Ian Faragher, Malcolm Steel, Wei Hong, Rachel Wong, Margaret Lee, Jeanne Tie, Suzanne Kosmider, Vanessa Wong, Sumitra Ananda, Azim Jalali, Peter Gibbs
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
122 Background: The patterns of metastatic relapse for Stage III colorectal cancer (CRC) are known to be influenced by the primary site and mutation status. Whether the use of adjuvant therapy also influences recurrence patterns, due to a variable chemotherapy impact by metastatic site, has yet to be explored. Patient age 70 years has consistently been associated with a lack of benefit from the addition of oxaliplatin to a fluoropyrimidine (FP) chemotherapy. Methods: Data from a multi-site CRC database that prospectively captures, patient, tumour, treatment and outcome data was examined. Patients with de novo metastatic or multiple primary tumours were excluded. Patterns of recurrence were ..View full abstract